The Hematopoietic and Lymphoid Systems

Hematopoiesis and the Hematopoietic System

Overview of the Hematopoietic Hierarchy

• Pluripotent Hematopoietic Stem Cells: All blood cells originate from these pluripotent cells in the bone marrow. They are capable of:

  • Self-renewal: The ability to maintain their own population.

  • In vitro differentiation: Generating specific lineages under laboratory conditions.

  • Cell transfer/In vivo cloning: Capacity to repopulate various lineages when transferred back into a living system.

• Major Lineages:

  • Lymphoid Stem Cell: Leads to the production of lymphoid cells.

    • T lymphocyte (T cell): Matures in the Thymus.

    • B lymphocyte (B cell): Matures into Plasma cells in the tissues.

    • NK cell (Natural Killer cell).

  • Trilineage Myeloid Stem Cell: Leads to the production of varied non-lymphoid cells.

    • Erythroid stem cell: Produces Erythrocytes (Red Blood Cells or RBCs).

    • Megakaryocyte: Fragments into Platelets (thrombocytes).

    • Granulocyte-monocyte lineage: Diverges into:

      • Monocytes: Which mature into Macrophages in tissues.

      • Neutrophils.

      • Eosinophils.

      • Basophils and Mast cells.

    • Dendritic cells.

Sites of Hematopoiesis Across Life Stages

• Embryo: Hematopoiesis begins in the Yolk sac.

• Fetus: The focus shifts to the Liver and the Spleen.

• Child: Most hematopoiesis occurs within the Bones (long and flat).

• Adult: Production is localized to specific axial bones:

  • Vertebrae

  • Ribs

  • Sternum

  • Pelvis

  • Calvarium (Skull)

Blood Composition and Clinical Assessment

Blood Components

• Fluid Component: Plasma.

• Cellular Component:

  • Red blood cells (erythrocytes): Specialized for oxygen transport via Hemoglobin (a complex molecule of four heme groups and four globins).

  • White blood cells (leukocytes): Part of the immune system.

  • Platelets (thrombocytes): Essential for clotting.

Laboratory Assessment of Hematologic Disorders

• Complete Blood Count (CBC): Performed with automated instruments to determine total cell counts. It includes RBC indices to classify anemia types:

  • Mean corpuscular volume (MCV): The average size of a red blood cell.

  • Mean corpuscular hemoglobin (MCH): The average amount of hemoglobin per cell.

  • Mean corpuscular hemoglobin concentration (MCHC): The concentration of hemoglobin in a given volume of packed RBCs.

• Reticulocyte count: Used to assess the bone marrow's response and capacity to produce new RBCs.

• Nutritional Diagnostics:

  • Serum iron, ferritin, and Total Iron Binding Capacity (TIBC): Used specifically for diagnosing iron deficiency anemia.

  • Vitamin $B_{12}$ and Folate levels: Used to diagnose megaloblastic anemia.

• Hemolysis Screening:

  • Peripheral smear and Coombs test: To evaluate immune-mediated hemolysis.

  • Osmotic fragility and genetic tests: Used for diagnosing hereditary spherocytosis.

  • Hemoglobin electrophoresis: Differentiates thalassemia and sickle cell disease.

• Leukemia and Lymphoma Diagnosis:

  • White blood cell differential: To detect leukocytosis (high count) or leukopenia (low count).

  • Bone marrow biopsy: Required for a definitive diagnosis.

  • Flow cytometry and cytogenetics: Used to identify specific markers and chromosomal abnormalities (e.g., the Philadelphia chromosome in CML).

  • Serum protein electrophoresis: Used for identifying multiple myeloma.

• Coagulation Tests:

  • Prothrombin Time (PT/INR): Evaluates the Extrinsic pathway.

  • Activated Partial Thromboplastin Time (aPTT): Evaluates the Intrinsic pathway.

  • Platelet count and function tests.

  • Factor assays: For Hemophilia A (Factor VIII) and Hemophilia B (Factor IX).

  • D-dimer and fibrinogen: Used for assessing Disseminated Intravascular Coagulation (DIC).

Disorders of Red Blood Cells: Anemia and Polycythemia

Anemia: Defined

• Anemia is a reduction in the oxygen-carrying capacity of the blood. It can be associated with:

  1. Appearance of abnormal hemoglobin.

  2. Reduced number of red blood cells.

  3. Structural abnormalities of the red blood cells.

Etiology and Pathogenesis of Anemia

• Decreased Hematopoiesis:

  • Bone marrow failure: Aplastic anemia and Myelophthisic anemia.

  • Nutrient Deficiencies: Lack of Vitamin $B_{12}$ and folic acid (megaloblastic anemia).

  • Iron Deficiency Anemia: The most common form. It is characterized as a hypochromic, microcytic anemia. Causes include:

    • Increased loss of iron (e.g., chronic bleeding).

    • Inadequate iron intake or absorption.

    • Increased iron requirements.

• Abnormal Hematopoiesis: Usually the consequence of genetic abnormalities.

  • Hemoglobinopathies and Thalassemia:

    • Sickle Cell Anemia: Red cells contain abnormal hemoglobin ($a\beta^s$) which leads to polymerization and sickling of the cell.

    • Thalassemia: Genetic imbalance in globin chain synthesis.

      • $\beta$-Thalassemia: Characterized by a large excess of $\alpha$ chains, causing significant pathology.

      • $\alpha$-Thalassemia: Characterized by gamma-globin (in neonates) and moderate excess of $\alpha$ depending on the severity; results in less sickling than other forms.

• Increased Loss or Destruction of RBCs:

  • Bleeding: Frank loss of blood.

  • Intrasplenic sequestration: The spleen traps RBCs.

  • Infections: For example, Malaria.

  • Hemolytic Anemia: Defined by increased RBC destruction (hemolysis).

    • Intracorpuscular defects: Sickle cell anemia, thalassemia, and Hereditary Spherocytosis.

      • Hereditary Spherocytosis: A primary genetic defect in proteins encoding ankyrin or the $\alpha$ or $\beta$ chain of spectrin. Peripheral blood shows spherocytes. Often treated with splenectomy.

    • Extracorpuscular defects: Destruction caused by external factors such as antibodies (Immune Hemolytic Anemias), infectious agents (malaria), mechanical factors (prostheses, DIC).

      • Immune Hemolytic Anemia: Mediated by antibodies against autoantigens, alloantigens, or neoantigens. Includes mismatched blood transfusions, hemolytic disease of the newborn, and autoimmune hemolytic anemias.

Megaloblastic Anemia

• Caused by a deficiency of Vitamin $B_{12}$ or Folic Acid.

• Vitamin $B_{12}$ deficiency:

  • Pernicious anemia: Specifically caused by a lack of gastric intrinsic factor.

  • Atrophic gastritis.

• Folic acid deficiency:

  • Inadequate dietary intake or malabsorption due to intestinal disease.

Polycythemia

• An overproduction of red blood cells (erythrocytosis).

• Primary Polycythemia (Polycythemia Vera): A bone marrow disease where atypical hematopoietic cell precursors proliferate despite low levels of Erythropoietin.

• Secondary Polycythemia: Driven by increased levels of Erythropoietin.

  • Hypoxia: Caused by heart disease, lung disease, or living at high altitude.

  • Excess Erythropoietin production: Resulting from tumors (producing androgens) or kidney diseases (renal/hepatic tumors).

Disorders of White Blood Cells and Plasma Cells

General Classifications

• Leukopenia: A reduction in white blood cell count.

• Leukocytosis: An increase in white blood cell count.

• Leukemia: Malignant disease involving WBC precursors in the bone marrow and peripheral blood. It typically involves infiltration of the marrow with malignant cells and increased numbers of immature blood cells in the periphery.

  • Subtypes: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL).

  • Complications: Anemia, recurrent infections, and uncontrollable bleeding.

• Lymphoma: Malignant diseases of lymphoid cells predominantly involving the lymph nodes. They can affect any age group and spread to the spleen, thymus, bone marrow, or other organs (extranodal spread).

  • Non-Hodgkin’s Lymphoma (NHL).

  • Hodgkin’s Lymphoma.

Etiology of Leukemia and Lymphoma

• Causes are largely unknown but associated with:

  • Viruses: HTLV-1 and Epstein-Barr Virus (EBV).

  • Chromosomal Translocations:

    • $t(8,14)$: Associated with Burkitt’s lymphoma.

    • $t(9,22)$: The Philadelphia chromosome, associated with Chronic Myelogenous Leukemia (CML).

Multiple Myeloma

• A malignant disease specifically of plasma cells.

• Typically affects patients older than $45$ years.

• Pathogenesis: Malignant plasma cells proliferate in the bone marrow and destroy the surrounding bone.

• Typical Findings:

  • Punched-out holes ("lytic lesions") in bone.

  • Bone fractures.

  • Hypercalcemia (due to bone resorption).

  • Renal failure.

  • Anemia and leukopenia.

Hemostasis and Bleeding Disorders

Normal Hemostasis

• Involves the interaction of Vascular factors, Platelet factors, and Coagulation factors.

• Systems in Balance:

  • Coagulation system: Leads to Thrombin generation and the formation of a Fibrin clot.

  • Fibrinolysis: The breakdown of clots by Plasmin.

• Imbalance results in either Thrombotic disease (excessive clotting) or Hemorrhage (excessive bleeding).

The Coagulation Cascade

• Intrinsic Pathway: Initiated by factors within the blood ($XII \rightarrow XI \rightarrow IX + VIII$). Assessed by aPTT.

• Extrinsic Pathway: Initiated by Tissue Factor and Factor VII. Assessed by Prothrombin Time (PT).

• Common Pathway: Where both pathways meet to convert Prothrombin (II) to Thrombin, which then converts Fibrinogen (I) to a Fibrin clot (XIII). Requires Calcium ($Ca^{++}$) and Lipids.

Platelet Disorders

• Increased removal: Found in conditions like Hypersplenism.

• Consumption of platelets: Often seen in Disseminated Intravascular Coagulation (DIC).

• Disorders of platelet function:

  • Congenital: Thrombasthenia.

  • Acquired: For example, in chronic renal failure.

Disseminated Intravascular Coagulation (DIC)

• Triggered by Injury (endothelial cell or tissue), Infection, Tumors, or Shock.

• Mechanism: Widespread activation of the coagulation cascade leads to Thrombi (microclots). This causes:

  1. Massive consumption of clotting factors.

  2. Activation of Plasmin (fibrinolysis).

• Outcome: The paradoxical combination of widespread clotting and severe Bleeding.

Clotting Factor Deficiencies

• Causes: Inadequate production, excessive consumption, or the action of anticoagulants.

• Hemophilia: Sex-linked congenital clotting factor deficiencies characterized by uncontrollable bleeding after trauma.

  • Hemophilia A: Deficiency of Factor VIII.

  • Hemophilia B: Deficiency of Factor IX.

  • Measured by prolonged aPTT while PT & INR often remain normal.

Overview of the Hematopoietic Hierarchy

• Pluripotent Hematopoietic Stem Cells: All blood cells originate from these stem cells located in the bone marrow. They are characterized by their ability to undergo:

  • Self-renewal: This process enables the maintenance of the stem cell population, ensuring a continuous supply of progenitor cells.

  • In vitro differentiation: In laboratory settings, they can differentiate into various committed progenitor cells that lead to specific blood lineages under controlled conditions.

  • Cell transfer/In vivo cloning: These stem cells can repopulate various lineages when transferred back into a living organism, demonstrating their plasticity and engraftment capability.

• Major Lineages:

  • Lymphoid Stem Cell: Responsible for producing lymphoid cells, crucial for the adaptive immune response.

    • T lymphocyte (T cell): These cells mature in the Thymus and are critical for cellular immunity, recognizing and attacking infected or cancerous cells.

    • B lymphocyte (B cell): These cells differentiate into Plasma cells which secrete antibodies and are vital for humoral immunity.

    • NK cell (Natural Killer cell): Plays a role in the innate immune response by destroying infected or tumor cells without prior sensitization.

  • Trilineage Myeloid Stem Cell: Responsible for producing a variety of non-lymphoid cells important for numerous bodily functions.

    • Erythroid stem cell: Produces Erythrocytes (Red Blood Cells or RBCs), which are primarily responsible for oxygen transport throughout the body via Hemoglobin.

    • Megakaryocyte: These large cells fragment into Platelets (thrombocytes), which are essential for hemostasis and wound healing.

    • Granulocyte-monocyte lineage: Differentiates into:

      • Monocytes: These cells mature into Macrophages in tissues, playing a crucial role in phagocytosis and immune response coordination.

      • Neutrophils: The most abundant type of white blood cell, essential for fighting bacterial infections.

      • Eosinophils: Important in combating parasitic infections and mediating allergic reactions.

      • Basophils and Mast cells: Involved in inflammatory responses, particularly those related to allergic reactions.

    • Dendritic cells: Act as antigen-presenting cells that activate the adaptive immune system, bridging innate and adaptive immunity.

Sites of Hematopoiesis Across Life Stages

• Embryo: Hematopoiesis begins in the Yolk sac, which is pivotal for early embryonic development.

• Fetus: The site shifts primarily to the Liver and the Spleen, where the production of blood cells increases significantly.

• Child: As the skeleton develops, most hematopoiesis occurs within the Bones (both long bones like the femur and flat bones like the pelvis).

• Adult: Hematopoiesis is localized to specific axial bones, including:

  • Vertebrae: Important for producing blood cells in adults.

  • Ribs: Contribute to blood cell formation.

  • Sternum: Typically is a site for bone marrow extraction in medical procedures.

  • Pelvis: Contains significant red marrow responsible for blood cell production.

  • Calvarium (Skull): Houses hemopoietic tissue involved in the maintenance of hematopoietic cell populations.

Blood Composition and Clinical Assessment

Blood Components

• Fluid Component: Plasma accounts for about 55% of blood volume and serves as a medium for transporting cells, nutrients, hormones, and waste products.

• Cellular Component:

  • Red blood cells (erythrocytes): Specialized for oxygen transport via Hemoglobin, which carries oxygen from the lungs to tissues and returns carbon dioxide for exhalation.

  • White blood cells (leukocytes): Integral to the immune system, defending against infections and foreign bodies.

  • Platelets (thrombocytes): Essential for blood clotting and the prevention of hemorrhage, responding to vascular injury by adhering to sites of damage.

Laboratory Assessment of Hematologic Disorders

• Complete Blood Count (CBC): This comprehensive test utilizes automated instruments to determine various cell counts, including:

  • RBC indices that classify types of anemia:
    
    

    • Mean corpuscular volume (MCV): Average size of a red blood cell, useful in categorizing anemia.

    • Mean corpuscular hemoglobin (MCH): Average amount of hemoglobin per red blood cell, indicating how well cells are oxygenated.

    • Mean corpuscular hemoglobin concentration (MCHC): Measures hemoglobin concentration in packed red blood cells, providing insight into iron deficiency.

• Reticulocyte count: Evaluates the bone marrow's response by measuring young red blood cells; an increased count suggests active erythropoiesis.

• Nutritional Diagnostics: Includes tests like:

  • Serum iron, ferritin, and Total Iron Binding Capacity (TIBC) for diagnosing iron deficiency anemia.

  • Vitamin $B_{12}$ and Folate levels: Crucial for diagnosing megaloblastic anemia.

• Hemolysis Screening: Evaluates the breakdown of red blood cells by conducting:

  • Peripheral smear and Coombs test to assess immune-mediated hemolysis.

  • Assessing osmotic fragility and performing genetic tests for diagnosing hereditary spherocytosis.

  • Hemoglobin electrophoresis differentiates thalassemia and sickle cell disease based on hemoglobin variants.

• Leukemia and Lymphoma Diagnosis:

  • White blood cell differential identifies leukocytosis (high count) or leukopenia (low count), aiding in identifying various neoplasms.

  • A Bone marrow biopsy is required for definitive diagnosis, helping differentiate between types of leukemia.

  • Techniques like flow cytometry and cytogenetics identify specific cell surface markers and chromosomal abnormalities, such as the Philadelphia chromosome present in CML.

  • Serum protein electrophoresis aids in diagnosing multiple myeloma by revealing abnormal proteins.

• Coagulation Tests:

  • Prothrombin Time (PT/INR): Evaluates the Extrinsic pathway, crucial for assessing bleeding risk.

  • Activated Partial Thromboplastin Time (aPTT): Evaluates the Intrinsic pathway, indicating issues with clotting factors.

  • Additional tests include monitoring Platelet count and function tests and conducting Factor assays for Hemophilia A (Factor VIII) and Hemophilia B (Factor IX).

  • D-dimer and fibrinogen levels assist in assessing Disseminated Intravascular Coagulation (DIC) and clotting factor abnormalities.

Disorders of Red Blood Cells: Anemia and Polycythemia

Anemia: Defined

• Anemia is characterized by a reduction in the oxygen-carrying capacity of the blood due to one or more factors such as:

  1. Altered hemoglobin structure or function.

  2. Decrease in the number of red blood cells.

  3. Structural abnormalities of red blood cells leading to failure in effective oxygen transport.

Etiology and Pathogenesis of Anemia

• Decreased Hematopoiesis:

  • Bone marrow failure observed in conditions like Aplastic anemia and Myelophthisic anemia.

  • Nutritional deficiencies such as varying levels of Vitamin $B_{12}$ and folic acid can cause suboptimal erythropoiesis, resulting in megaloblastic anemia.

  • Iron Deficiency Anemia, the most prevalent form, characterized by hypochromic, microcytic anemia influenced by factors such as chronic blood loss, deficient dietary intake, or increased demands during growth or menstruation.

• Abnormal Hematopoiesis: Commonly results from genetic complications affecting hemoglobin production:

  • Hemoglobinopathies and Thalassemia: Conditions like Sickle Cell Anemia, where abnormal hemoglobin ($a\beta^s$) leads to red cell polymerization, causing sickle-shaped cells, and Thalassemia, characterized by a genetic imbalance in globin chain synthesis which can result in severe anemia depending on chain incompatibilities.

• Increased Loss or Destruction of RBCs:

  • Bleeding due to injuries or chronic conditions leading to significant blood loss.

  • Intrasplenic sequestration, where the spleen improperly traps red blood cells, causing a decrease in circulating erythrocytes.

  • Hemolytic Anemia, which indicates increased destruction of red blood cells either because of intrinsic defects (as seen in Sickle Cell Anemia, Thalassemia, and Hereditary Spherocytosis) or due to external factors like immune-mediated destruction (Immune Hemolytic Anemias) or infections like Malaria.

Megaloblastic Anemia

• This type results from deficiencies in either Vitamin $B_{12}$ or Folate and can manifest through:

  • Vitamin $B_{12}$ deficiency resulting in conditions like Pernicious anemia, caused specifically by a lack of gastric intrinsic factor.

  • Folic acid deficiency, often resulting from inadequate dietary intake or malabsorption issues stemming from gastrointestinal diseases.

Polycythemia

• Defined as an overproduction of red blood cells (erythrocytosis). It can be classified into:

  • Primary Polycythemia (Polycythemia Vera): A myeloproliferative disorder where there is a continued proliferation of the bone marrow’s hematopoietic cells despite low serum Erythropoietin levels, leading to increased blood viscosity and potential thrombotic risks.

  • Secondary Polycythemia: Often driven by elevated levels of Erythropoietin due to underlying conditions such as chronic hypoxia associated with heart or lung disease or from tumorigenic processes that stimulate excess erythropoietin production.

Disorders of White Blood Cells and Plasma Cells

General Classifications

• Leukopenia indicates a reduced white blood cell count, potentially compromising the immune system.

• Leukocytosis refers to an increase in white blood cell count, often as a response to infection or other diseases.

• Leukemia represents a category of malignant diseases involving precursors of white blood cells in both the bone marrow and peripheral blood, commonly characterized by the infiltration of the marrow with immature neoplastic cells and resultant symptoms of anemia, recurrent infections, and uncontrolled bleeding.

  • Subtypes: Include Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), each with distinct pathophysiological characteristics and treatment approaches.

• Lymphoma: Represents a heterogeneous group of malignant diseases of lymphoid cells, predominantly involving lymph nodes but with potential extranodal transformation, affecting various population demographics.

  • Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Lymphoma are distinguished types with varied clinical presentations and prognoses.

Etiology of Leukemia and Lymphoma

• The etiology remains largely elusive, yet associations include:

  • Viruses such as HTLV-1 and Epstein-Barr Virus (EBV), recognized carcinogenic agents in certain contexts.

  • Chromosomal Translocations associated with leukemias:

    • e.g., $t(8,14)$, often linked to Burkitt’s lymphoma.

    • $t(9,22)$, the famous Philadelphia chromosome tied to Chronic Myelogenous Leukemia (CML).

Multiple Myeloma

• A specialized malignant disorder affecting plasma cells, with a typical onset in individuals above 45 years old.

• Pathogenesis involves the clonal proliferation of malignant plasma cells in the bone marrow, leading to bone destruction and associated phenomena.

• Typical Findings include:

  • Punched-out holes or lytic lesions in bone indicative of ongoing bone resorption.

  • Increased rates of bone fractures, often due to weakened structures.

  • Hypercalcemia, a recurring consequence of bone degradation leading to elevated calcium levels in the blood.

  • Renal failure, commonly secondary to increased production of monoclonal proteins that overwhelm renal filtration.

  • Coexisting anemia and leukopenia, often complicating the diagnosis and management of the disease.

Hemostasis and Bleeding Disorders

Normal Hemostasis

• Involves precise interactions among Vascular factors, Platelet factors, and Coagulation factors to maintain blood in a fluid state while allowing clot formation when necessary.

• Systems in Balance:

  • The Coagulation system generates Thrombin, facilitating the conversion of Fibrinogen to Fibrin, creating stable clot structures.

  • Fibrinolysis, involves the breakdown of fibrin clots via Plasmin, ensuring normal vascular patency post-hemostatic events.

• Imbalance within these systems leads either to Thrombotic disease (excessive clotting) or Hemorrhage (excessive bleeding).

The Coagulation Cascade

• Comprises

  • Intrinsic Pathway: Initiated by factors within the blood leading to activation of more factors following the sequence ($XII \rightarrow XI \rightarrow IX + VIII$), chiefly assessed by aPTT.

  • Extrinsic Pathway: Initiated promptly upon vascular injury by Tissue Factor and Factor VII, assessed through Prothrombin Time (PT).

  • Common Pathway: Represents the convergence where intrinsic and extrinsic pathways enroll to convert Prothrombin (II) into Thrombin, facilitating fibrin clot formation, requiring Calcium ($Ca^{++}$) and Lipids for efficiency.

Platelet Disorders

• Encompasses various conditions, including:

  • Increased removal: Such as in Hypersplenism, where an enlarged spleen leads to sequestration of platelets.

  • Consumption of platelets in situations like Disseminated Intravascular Coagulation (DIC), where clotting factors are excessively consumed, leading to bleeding disorders.

  • Disorders of platelet function categorized into:

    • Congenital (e.g., Thrombasthenia, a hereditary defect) and Acquired conditions, for example, chronic renal failure affecting platelet reactivity.

Disseminated Intravascular Coagulation (DIC)

• Triggered by various pathological insults including Injury, Infection, Tumors, or Shock, leading to considerable systemic effects.

• Mechanism: Involves widespread activation of the coagulation cascade, producing microclots throughout the vasculature causing tissue hypoxia.

  • Results in:

    1. Massive consumption of clotting factors leading to bleeding diathesis.

    2. Activation of the fibrinolysis process, exacerbating the bleeding risk.

• Outcome is a paradoxical combination of widespread clotting (thrombosis) throughout the microcirculation and severe Bleeding due to depleted clotting factors and platelets.

Clotting Factor Deficiencies

• Causes can stem from inadequate production, excessive consumption or external factors such as anticoagulants.

• Hemophilia: A group of sex-linked congenital disorders characterized by deficiencies in specific clotting factors leading to massive bruising, prolonged bleeding after trauma:

  • Hemophilia A: Characterized by a deficiency of Factor VIII, leading to prolonged bleeding times.

  • Hemophilia B: Aligned with a deficiency of Factor IX.

  • These conditions are primarily evaluated through increased aPTT while PT & INR often remain normal, providing differentiation from other bleeding disorders.